Abstract
Diffuse large B-cell lymphoma (DLBCL) is characterized by its clinical and biological heterogeneity. Although the International Prognostic Index (IPI) provides a clinical model for risk stratification of patients with DLBCL, notable variability in outcome is still observed within the same IPI category. Tumor-infiltrating macrophages (also called Tumor-associated macrophages) are the major component in the microenvironment of DLBCL. Their correlation with the prognosis of DLBCL remains controversial. Using a CD68 antibody in immunohistochemical analysis, we studied the expression of CD68 in 112 Chinese patients with DLBCL, with 65 patients (58%) categorized as low CD68 expression and 47 patients (42%) as high CD68 expression. The complete response (CR) rate of patients with low CD68 expression was higher than that with high CD68 expression (66.1% vs. 51.6%), but there was no statistical significance (P = 0.060). The median survival time of patients with low CD68 expression was not achieved and that of high expression was 41 months (P = 0.029). The results suggest that higher expression of CD68 tended to yield poor treatment outcome of DLBCL.
Similar content being viewed by others
References
Coiffier B. Standard treatment of advanced-stage diffuse large B-cell lymphoma. Semin Hematol. 2006;43(4):213–20.
Coiffier B. State-of-the-art therapeutics: diffuse large B-celllymphoma. J Clin Oncol. 2005;23:6387–93.
Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–33.
Shipp M, Harrington D, Anderson J, et al. A predictive model for aggressive lymphoma: the international NHL prognostic factors project. N Engl J Med. 1993;329:987–94.
Chen JJ, Lin YC, Yao PL, et al. Tumor-associated macrophages: the double-edged sword in cancer progression [J]. J Clin Oncol. 2005;23(5):953–64.
Bingle L, Brown NJ, Lewis CE. The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies [J]. J Pathol. 2002;196(3):254–65.
Mantovani A, Allavena P, Siea A, et al. Tumor-associated macrophages as a prototype type II polarized phagocyte population:role in tumor progression [J]. Eur J Cancer. 2004;40(11):1660–7.
Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008;84(3):623–30.
Zeni E, Mazzetti L, Miotto D, et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J. 2007;30(4):627–32.
Senapati S, Rachagani S, Chaudhary K, et al. Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene. 2010;29(9):1293–302.
Ohno S, Inagawa H, Dhar DK, et al. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res. 2003;23(6):5015–22.
Funada Y, Noguchi T, Kikuchi R, et al. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep. 2003;10(2):309–13.
Farinha P, Masoudi H, Brian F, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM)content is an independent predictor of survival in follicular lymphoma(FL). Blood. 2005;106:2169–74.
Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362(10):875–85.
Zhang W, Wang L, Zhou D, et al. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymphoma. 2011;52(1):46–52.
Hasselblom S, Hansson U, Sigurdardottir M, et al. Expression of CD68 + tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int. 2008;58(8):529–32.
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.
Linderoth J, Edén P, Ehinger M, Valcich J, et al. Genes associated with the tumor microenvironment are differentially expressed in cured versus primary chemotherapy -refractory diffuse large B-cell lymphoma. Br J Haematol. 2008;141(4):423–32.
Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in Large-B-Cell Lymphomas. N Engl J Med. 2008;359(22):2313–23.
Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.
Taskinen M, Karjalainen-Lindsberg ML, Nyman H, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007;13(19):5784–9.
Canioni D, Salles G, Mounier N, Brousse N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS 2000 trail. J Clin Oncol. 2008;26(3):440–6.
Meyer PN, Fu K, Greiner T, et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-Cell lymphoma treated with Rituximab. Am J Clin Pathol. 2011;135:54–61.
Niino D, Komohara Y, Murayama T, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int. 2010;60:278–83.
Acknowledgments
We thank Ms. Yuwen Du (Zhongshan School of Medicine, Sun Yat-sen University) for the linguistic revision and proofreading of this paper.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Qi-chun Cai and Hong Liao are co-first authors and contributed equally to this article.
Rights and permissions
About this article
Cite this article
Cai, Qc., Liao, H., Lin, Sx. et al. High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol 29, 2317–2322 (2012). https://doi.org/10.1007/s12032-011-0123-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-011-0123-6